Role of Lobectomy in Early Stage NSCLC
- Ginsberg
RJ, Rubinstein LV, Lung Cancer Study Group. Randomized trial of lobectomy
versus limited resection for T1 N0 non-small cell lung cancer. The Annals
of Thoracic Surgery. 1995 Sep 1;60(3):615-23.
- Gajra
A, Newman N, Gamble GP, Kohman LJ, Graziano SL. Effect of number of lymph
nodes sampled on outcome in patients with stage I non–small-cell lung
cancer. Journal of clinical oncology. 2003 Mar 15;21(6):1029-34.
No Role of Adjuvant Treatment In Stage IA NSCLC
- Pignon
JP, Tribodet H, Scagliotti GV, Douillard JY, Shepherd FA, Stephens RJ, et
al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE
Collaborative Group. J Clin Oncol. 2008;26(21):3552-9.
Role of Adjuvant Chemo in Stage IB NSCLC
- Strauss
GM, Herndon JE, 2nd, Maddaus MA, Johnstone DW, Johnson EA, Harpole DH, et
al. Adjuvant paclitaxel plus carboplatin compared with observation in
stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and
Leukemia Group B, Radiation Therapy Oncology Group, and North Central
Cancer Treatment Group Study Groups. J Clin Oncol. 2008;26(31):5043-51.
Role of Adjuvant Chemo In Stage II-IIIA NSCLC
- Pignon
JP, Tribodet H, Scagliotti GV, Douillard JY, Shepherd FA, Stephens RJ, et
al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE
Collaborative Group. J Clin Oncol. 2008;26(21):3552-9.
- Scagliotti
GV, Fossati R, Torri V, Crino L, Giaccone G, Silvano G, et al. Randomized
study of adjuvant chemotherapy for completely resected stage I, II, or
IIIA non-small-cell Lung cancer. J Natl Cancer Inst. 2003;95(19):1453-61.
- Arriagada
R, Dunant A, Pignon JP, Bergman B, Chabowski M, Grunenwald D, Kozlowski M,
Le Péchoux C, Pirker R, Pinel MI, Tarayre M. Long-term results of the
international adjuvant lung cancer trial evaluating adjuvant
Cisplatin-based chemotherapy in resected lung cancer. Journal of Clinical
Oncology. 2009 Nov 23;28(1):35-42.
- Butts
CA, Ding K, Seymour L, Twumasi-Ankrah P, Graham B, Gandara D, Johnson DH,
Kesler KA, Green M, Vincent M, Cormier Y. Randomized phase III trial of
vinorelbine plus cisplatin compared with observation in completely
resected stage IB and II non–small-cell lung cancer: updated survival
analysis of JBR-10. Journal of clinical oncology. 2009 Nov 23;28(1):29-34.
- Douillard
JY, Rosell R, De Lena M, Carpagnano F, Ramlau R, Gonzales-Larriba JL, et
al. Adjuvant vinorelbine plus cisplatin versus observation in patients
with completely resected stage IB-IIIA non-small-cell lung cancer
(Adjuvant Navelbine International Trialist Association [ANITA]): a
randomised controlled trial. Lancet Oncol. 2006;7(9):719-27.
Role of Post-Operative RT in Early Stage NSCLC with Positive margins
- Wang
EH, Corso CD, Rutter CE, Park HS, Chen AB, Kim AW, et al. Postoperative
Radiation Therapy Is Associated With Improved Overall Survival in
Incompletely Resected Stage II and III Non-Small-Cell Lung Cancer. J Clin
Oncol. 2015;33(25):2727-34.
SBRT in Early Stage NSCLC [T1/T2-N0]
- Chang
JY, Senan S, Paul MA, Mehran RJ, Louie AV, Balter P, et al. Stereotactic
ablative radiotherapy versus lobectomy for operable stage I non-small-cell
lung cancer: a pooled analysis of two randomised trials. Lancet Oncol.
2015;16(6):630-7.
Role of Post-Operative RT in Early Stage NSCLC with N2 disease
- Douillard
JY, Rosell R, De Lena M, Riggi M, Hurteloup P, Mahe MA, et al. Impact of
postoperative radiation therapy on survival in patients with complete
resection and stage I, II, or IIIA non-small-cell lung cancer treated with
adjuvant chemotherapy: the adjuvant Navelbine International Trialist
Association (ANITA) Randomized Trial. Int J Radiat Oncol Biol Phys.
2008;72(3):695-701.
Role of CCRT in Locally Advance NSCLC
- Curran
WJ, Jr., Paulus R, Langer CJ, Komaki R, Lee JS, Hauser S, et al.
Sequential vs. concurrent chemoradiation for stage III non-small cell lung
cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst.
2011;103(19):1452-60.
- Auperin A, Le Pechoux C, Rolland E, Curran WJ, Furuse K, Fournel P, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol. 2010;28(13):2181-90.
Palliative RT for Good PS in Stage IV NSCLC [39 Gy in 13 Fr]
- Macbeth
FR, Bolger JJ, Hopwood P, Bleehen NM, Cartmell J, Girling DJ, et al.
Randomized trial of palliative two-fraction versus more intensive
13-fraction radiotherapy for patients with inoperable non-small cell lung
cancer and good performance status. Medical Research Council Lung Cancer
Working Party. Clin Oncol (R Coll Radiol). 1996;8(3):167-75.
Palliative RT for Poor PS in Stage IV NSCLC [10 Gy in 1 Fr]
- A
Medical Research Council (MRC) randomised trial of palliative radiotherapy
with two fractions or a single fraction in patients with inoperable
non-small-cell lung cancer (NSCLC) and poor performance status. Medical
Research Council Lung Cancer Working Party. Br J Cancer.
1992;65(6):934-41.